Repligen
RGEN
#2126
Rank
$8.85 B
Marketcap
$157.39
Share price
-2.64%
Change (1 day)
-2.19%
Change (1 year)
Categories

Repligen (RGEN) - P/B ratio

P/B ratio as of December 2025 : 4.25

According to Repligen 's latest financial reports the company has a price-to-book ratio of 12.5155.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Repligen - P/B ratio (from 2001 to 2025)

P/B ratio by year

Year P/B ratio Change
2025-12-31N/A-100%
2024-12-314.13-19.1%
2023-12-315.113.84%
2022-12-314.92-41.2%
2021-12-318.3722.02%
2020-12-316.8650.85%
2019-12-314.5520.81%
2018-12-313.7640.83%
2017-12-312.67-56.75%
2016-12-316.18-18.64%
2015-12-317.5930.75%
2014-12-315.8138.56%
2013-12-314.1980%
2012-12-312.3348.22%
2011-12-311.57-25.05%
2010-12-312.1011.94%
2009-12-311.8713.48%
2008-12-311.65-45.55%
2007-12-313.03-10.17%
2006-12-313.37-27.58%
2005-12-314.6632.78%
2004-12-313.51-18.64%
2003-12-314.3135.83%
2002-12-313.17

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
Novavax
NVAX
-6.81-260.22%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
1.69-60.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
5.07 19.25%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
16.7 293.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
4.20-1.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
5.74 34.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
1.58-62.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
4.64 9.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
24.3 470.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
2.75-35.27%๐Ÿ‡บ๐Ÿ‡ธ USA